Is JAZZ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.

JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis - Financials

Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of October 19, 2026, JAZZ trades at $208.35 with a market cap of $13.65B and a P/E ratio of 25.73. JAZZ moved -0.90% today. Year to date, JAZZ is +20.38%; over the trailing twelve months it is +53.19%. Its 52-week range spans $95.49 to $266.38. Analyst consensus is strong buy with an average price target of $298.17. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are JAZZ's key financials?

JAZZ financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. JAZZ recently traded at $208.35. Market cap is $13.65B. P/E ratio is 25.73. Revenue is $4.07B.

JAZZ Key Metrics

Key financial metrics for JAZZ
Metric	Value
Price	$208.35
Market Cap	$13.65B
P/E Ratio	25.73
EPS	$9.06
Dividend Yield	0.00%
52-Week High	$266.38
52-Week Low	$95.49
Volume	548.38K
Avg Volume	0
Revenue (TTM)	$4.07B
Net Income	$560.12M
Gross Margin	0.00%

JAZZ Analyst Consensus

18 analysts cover JAZZ: 0 strong buy, 17 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $298.17.

Common questions about JAZZ

What are JAZZ's key financials?: JAZZ financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. JAZZ recently traded at $208.35. Market cap is $13.65B. P/E ratio is 25.73. Revenue is $4.07B.
Is JAZZ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.